false
0000827871
0000827871
2023-11-27
2023-11-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section
13 or 15(d)
of the Securities
Exchange Act of 1934
Date of Report (Date of
earliest event reported): November 27, 2023
Eagle Pharmaceuticals, Inc.
(Exact name of registrant
as specified in its charter)
Delaware |
001-36306 |
20-8179278 |
(State
or other jurisdiction |
(Commission File Number) |
(IRS Employer Identification No.) |
of
incorporation) |
|
|
50 Tice Boulevard, Suite 315
Woodcliff Lake, NJ |
|
07677 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s
telephone number, including area code: (201) 326-5300
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name
of each exchange on which registered |
Common Stock, par value $0.001 per share |
|
EGRX |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Explanatory Note
On November 29, 2023, Eagle Pharmaceuticals (the “Company”) filed a Current Report on Form 8-K (the “Original Form 8-K”), with the U.S. Securities and Exchange Commission (the
“SEC”), announcing the appointment on November 27, 2023 of Michael Graves as Interim Executive Chairman of the Board
of Directors of the Company (the “Board”) and Interim Principal Executive Officer of the Company in connection with Mr. Tarriff’s
resignation from his positions with the Company and the Board. This Amendment No. 1 to Current Report on Form 8-K
(“Amendment No. 1”) amends the Original Form 8-K in order to supplement the Company’s disclosure under Item
5.02 of the Original Form 8-K with respect to the compensation terms for Mr. Graves’s new role, which such terms were
not known at the time of filing the Original Form 8-K. The Original Form 8-K otherwise remains unchanged and does not otherwise
reflect events occurring after the original filing of the Form 8-K except as set forth in this Amendment No. 1.
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
In connection with
such appointment of Mr. Graves as the Interim Executive Chairman of the Board and Interim Principal Executive Officer of the
Company, on December 21, 2023, the Company and Mr. Graves entered into an offer letter (the “Offer Letter”)
providing the following compensation terms, commencing retroactively as of November 27, 2023 (the “Effective
Date”): (i) a monthly compensation of $110,000 for the Term (as defined below); and (ii) eligibility to receive a
one-time nonqualified stock option to purchase 293,000 shares of the Company’s common stock, which was granted on
December 21, 2023 in connection with the execution of the Offer Letter. The option will vest in equal monthly installments over
a one-year period measured from the Effective Date subject to his Continuous Service (as defined in the Company's 2014 Equity
Incentive Plan (the “Plan”)), and will accelerate in full upon (i) his death or Disability (as defined in the
Plan), (ii) a Change in Control (as defined in the Plan) or (iii) Mr. Graves’s termination without Cause (as
defined in the Plan) from the Interim Principal Executive Officer and Interim Executive Chairman roles on or within three months
prior to a Change in Control. The nonqualified stock option award described above is subject to the terms and conditions of the
Plan, previously adopted and disclosed by the Company and filed as Exhibit
10.1 to the Company’s Current
Report on Form 8-K filed with the SEC on August 10, 2015, and the form of option award agreement, previously adopted and
disclosed by the Company and filed as
Exhibit 10.3 to the Company’s Current
Report on Form 8-K filed with the SEC on December 21, 2015. During Mr. Graves’s Term as Interim Executive Chairman of
the Board and Interim Principal Executive Officer of the Company, Mr. Graves will not be eligible for participation in the
Company’s executive bonus program. Mr. Graves will also not be eligible to participate in the Company’s severance
plans. During the Term, Mr. Graves will not be eligible for compensation (either in the form of cash or equity) under the
Company’s non-employee director compensation program, although he remains on the Board, and equity previously granted to him
in his capacity as a non-employee director continues to vest. Mr. Graves’s employment is on an at-will basis, with an
expected term of less than 12 months (the “Term”), which may be terminated sooner or may be extended by mutual
agreement.
The Company and Mr. Graves previously entered into the Company’s
standard director and officer indemnification agreement, in the form previously adopted and disclosed by the Company and filed as Exhibit 10.1
to the Company’s Registration Statement on Form S-1 filed with the SEC on December 20, 2013, in connection with his prior
service on the Board.
The description of the Offer Letter is only
a summary, does not purport to be complete and is qualified in its entirety by the full text of the Offer Letter, a copy of which is attached
hereto as Exhibit 10.1 and incorporated herein by reference.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: December 22, 2023 |
EAGLE PHARMACEUTICALS, INC. |
|
|
|
By: |
/s/ Brian Cahill |
|
|
Brian Cahill |
|
|
Chief Financial Officer |
Exhibit 10.1
December 21, 2023
VIA EMAIL
Michael Graves
Dear Mike:
This agreement contains the terms of your position
as Interim Principal Executive Officer of Eagle Pharmaceuticals, Inc. (the “Company”) and Interim Executive
Chairman (the “Interim Executive Chair”) of the Board of Directors of the Company (the “Board”)
with an effective date of November 27, 2023 (the “Effective Date”).
As Interim Executive Chair, you will report directly
to the Board and will perform such duties, consistent with the Interim Executive Chair position, as will reasonably be assigned to you
by the Board. This is intended to be a temporary position with an expected term of less than 12 months (the “Term”),
though this is an at-will appointment and may be terminated sooner or extended, by mutual agreement. During the Term, you will remain
a member of the Board, of which you were previously the Chair, and immediately following the Term you will return to your position as
non-executive Chairman of the Board.
You will perform your services hereunder primarily
from your home but agree to perform your services from the Company’s offices in New Jersey from time to time, in accordance with
the needs of the business. You may be required to travel from time to time. You will be eligible for reimbursement of reasonable, necessary
expenses incurred by you in connection with the performance of your duties hereunder in accordance with the Company’s expense reimbursement
policies and procedures.
During your Term as Interim Executive Chair, you
will receive compensation at the rate of $110,000.00 per month (equivalent to annualized compensation of $1,320,000.00) which will be
paid in accordance with the Company’s regular payroll practices. During the Term, you will not be eligible for participation in
the Company’s executive bonus program, as the compensation set forth above is inclusive of a bonus. You will also not be eligible
to participate in the Company’s severance plans. Even if you are eligible to participate in the Company’s health and welfare
plans in accordance with the terms and eligibility criteria of such plans, you have disclosed that you do not intend to participate in
the Company’s health and welfare plans given your existing coverage through other employment or self-employment. Your employment
will be subject to the Company’s personnel policies and procedures as they may be interpreted, adopted, revised or deleted from
time to time in the Company’s sole discretion, but only to the extent that such policies and procedures are not inconsistent with
the terms of this letter.
During the Term, you will not be eligible for
compensation (either in the form of cash or equity) under the Company’s non-employee director compensation program. You have previously
been granted one or more equity awards by the Company in connection with your service as a director, which grant(s) shall continue
to vest during the Term and which shall continue to be governed in all respects by the terms of the applicable equity agreements, grant
notices, and equity plans.
Upon approval by the Board or authorized committee
thereof, you will be granted a nonqualified stock option to purchase 293,000 shares of the Company’s common stock (the “Option”)
under the Company’s 2014 Equity Incentive Plan (the “Plan”). The Option will have a per share exercise
price equal to the Fair Market Value (as defined in the Plan) on the date of grant of the Option and shall vest and become exercisable
in equal monthly installments over a one year period measured from the Effective Date, subject to your Continuous Service (as defined
in the Plan, which for clarity includes your service as a non-employee member of the Board). The Option will accelerate vesting and exercisability
in full upon your death or Disability (as defined in the Plan) or upon a Change in Control (as defined in the Plan) or in the event your
employment as Interim Executive Chair is terminated by the Company without Cause (as defined in the Plan) within the three months prior
to a Change in Control. The Option will be governed by the terms of the Plan and an associated stock option grant agreement.
The existing indemnification agreement (along
with any applicable confidentiality or non-disclosure agreement) between you and the Company will continue to govern your service as Interim
Executive Chair. You have disclosed to the Board that you currently serve as the Executive Chair of Nanocopoeia, Inc. and the parties
acknowledge that such work does not conflict with or otherwise restrict your ability to become Interim Executive Chair of the Company
and fulfill your duties to the Company in such capacity, and you may continue to hold such position during the Term. Nothing in this offer
should be construed to interfere with or otherwise restrict in any way the rights of the Company and the Company’s stockholders
to remove any individual from the Board at any time in accordance with the Company’s certificate of incorporation, bylaws, any applicable
agreements and applicable law.
You acknowledge that as a result of your service
on the Board and as Interim Executive Chair you have obtained and will obtain confidential information and proprietary information relating
to or provided by the Company and its affiliates. During and after the Term, you shall not use for your benefit or disclose confidential
information, proprietary information, knowledge or data relating to or provided by the Company and its affiliates and you agree to execute
the Company’s standard employee non-disclosure agreement upon the Company’s reasonable request.
To indicate your acceptance of the Company’s
offer, please sign and date this letter in the space provided below and return it to me. This letter sets forth the terms of your service
as Interim Executive Chair and supersedes any prior representations or agreements on this subject matter, whether written or oral. This
letter will be construed and interpreted in accordance with the laws of the State of New Jersey. This letter may not be modified or amended
except by a written agreement, signed by an officer of the Company or an authorized director of the Board and by you.
We look forward to continue working with you in your new capacity.
Sincerely,
Eagle
Pharmaceuticals, Inc. |
|
|
|
By:
|
/s/
Robert Glenning |
|
|
Robert
Glenning |
|
|
Chair
of the Compensation Committee of
the Board of Directors |
|
I HAVE READ, UNDERSTAND AND AGREE FULLY TO THE
FOREGOING AGREEMENT:
/s/ Michael Graves |
|
Michael Graves |
|
v3.23.4
Cover
|
Nov. 27, 2023 |
Cover [Abstract] |
|
Document Type |
8-K/A
|
Amendment Flag |
false
|
Document Period End Date |
Nov. 27, 2023
|
Entity File Number |
001-36306
|
Entity Registrant Name |
Eagle Pharmaceuticals, Inc.
|
Entity Central Index Key |
0000827871
|
Entity Tax Identification Number |
20-8179278
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
50 Tice Boulevard
|
Entity Address, Address Line Two |
Suite 315
|
Entity Address, City or Town |
Woodcliff Lake
|
Entity Address, State or Province |
NJ
|
Entity Address, Postal Zip Code |
07677
|
City Area Code |
201
|
Local Phone Number |
326-5300
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.001 per share
|
Trading Symbol |
EGRX
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Eagle Pharmaceuticals (NASDAQ:EGRX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024